- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01661855
A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD (RILISE)
March 17, 2017 updated by: Evdokia Anagnostou
A Pilot Study of Riluzole vs. Placebo in the Treatment of Children and Adolescents With Autism Spectrum Disorders
This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
There are no pharmacologic treatments available for social function deficits in individuals with Autism Spectrum Disorders (ASD).
The data for pharmacologic treatment of repetitive behaviors in this disorder has also become difficult to interpret given that the last two large multisite trials of selective serotonin reuptake inhibitors (SSRIs) in autism are reported to be negative for the treatment of repetitive behaviors.
Only the associated symptom of irritability has 2 drugs with FDA indications whereas no systematic data exists on the pharmacologic treatment of anxiety in ASD, and response to rates to stimulants for hyperactivity are lower than what is seen in attention deficit hyperactivity disorder (ADHD).
In addition, there are no biological markers of treatment response identified in this population at this point.
This study will examine the potential efficacy and safety of riluzole for core and associated symptom domains of autism and will explore biological markers of safety and treatment response.
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8S 4K1
- Offord Centre for Child Studies
-
London, Ontario, Canada, N6A 5W9
- Lawson Health Research Institute
-
Toronto, Ontario, Canada, M4G 1R8
- Holland Bloorview Kids Rehabilitation Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female outpatients 6-17 years of age inclusive, with a mental age equivalent ≥ 18 months at Screening visit.
- Meet Diagnostic and Statistical Manual (DSM-IV) criteria for an ASD.
- Have a Clinician's Global Impression-Severity (CGI-S) score ≥ 4 (moderately ill) at Screening.
If already receiving stable interventions must meet the following criteria:
- If already receiving stable concomitant medications affecting behavior, must be on a stable dose during the preceding 1 month prior to Screening (with the exception of fluoxetine, where a period of 6 weeks is needed), and will not electively initiate new or modify ongoing medications for study duration.
- If already receiving stable non-pharmacological educational, behavioral, and/or dietary interventions, have continuous participation during the preceding 3 months prior to Screening, and not electively initiate new or modify ongoing interventions for the duration of the study.
- Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Investigator.
- Ability to complete assessments- fluency in English (parent; patient, if verbal).
- Consent to participate in the Province of Ontario Neurodevelopmental (POND) study and commitment to completing as many stages as possible of the phenotyping measures (Stages 1, 2 and 3), genomics component, and interest in being imaged through POND.
- Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian.
Exclusion Criteria:
- Pregnant female patients; sexually active female patients on inadequate birth control.
- Patients with a serious medical condition that, based on Investigator judgment, might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. Patients with evidence or history of malignancy or any significant hematological, endocrine, cardiovascular (including any rhythm disorder), respiratory, renal, hepatic, or gastrointestinal disease, not including mild common pediatric diseases in these areas that are stable (e.g. mild asthma, constipation, etc.).
- Patients with unstable epilepsy (i.e. seizures occurring within the last 6 months), or patients with epilepsy who are not on stable doses of antiepileptic medications (i.e. dose changes within the last 3 months).
- Patients with hypersensitivity to riluzole or any components of its formulation.
- Patients with one or more of the following: HIV, Hepatitis B virus, Hepatitis C virus, hemophilia (bleeding problems, recent nose and brain injuries), abnormal blood pressure (hypotension or hypertension), drug abuse, immunity disorder, major depressive episode or psychosis.
- Patients unable to tolerate venipuncture procedures for blood sampling.
- Patients receiving concomitant medications that specifically target the glutamate system (e.g. memantine, d-cycloserine), or decrease the elimination of riluzole (e.g. theophylline, quinolones), less than 30 days prior to the screening visit.
- Patients actively enrolled in another intervention study.
- Patients who are unable to swallow pills.
- Patients who have elevated liver enzymes ≥ 3 times the normal amount before the study begins.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
|
Active Comparator: Riluzole
|
50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of riluzole vs. placebo on measures of social function
Time Frame: 12 weeks
|
This will be measured by the Aberrant Behavior Checklist (ABC) - Lethargy / Social Withdrawal Subscale
|
12 weeks
|
Efficacy of riluzole vs. placebo on measures of repetitive behaviors
Time Frame: 12 weeks
|
This will be measured by the Child Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
|
12 weeks
|
Efficacy of riluzole vs. placebo on measures of repetitive behaviors
Time Frame: 12 weeks
|
This will be measured by the Repetitive Behavior Scale (RBS-R)
|
12 weeks
|
Safety and tolerability of riluzole in children and adolescents with ASD
Time Frame: 12 Weeks
|
This will be measured by the Safety Monitoring Uniform Report Form (SMURF)
|
12 Weeks
|
Safety and tolerability of riluzole in children and adolescents with ASD
Time Frame: 12 Weeks
|
This will be measured by the Clinical Global Impressions - Improvement Scale - Global (CGI-I-Global)
|
12 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Evdokia Anagnostou, M.D., Holland Bloorview Kids Rehabilitation Hospital
- Principal Investigator: Robert Nicolson, M.D., University of Western Ontario, Lawson Health Research Institute
- Principal Investigator: Terry Bennett, M.D., McMaster University; Offord Centre for Child Studies
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
July 26, 2012
First Submitted That Met QC Criteria
August 9, 2012
First Posted (Estimate)
August 10, 2012
Study Record Updates
Last Update Posted (Actual)
March 20, 2017
Last Update Submitted That Met QC Criteria
March 17, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Autistic Disorder
- Autism Spectrum Disorder
- Child Development Disorders, Pervasive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Neuroprotective Agents
- Protective Agents
- Anticonvulsants
- Riluzole
Other Study ID Numbers
- RILISE-07-2013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorders
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
Emory UniversityNational Institute of Mental Health (NIMH)Terminated
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Florida State University; Autism...CompletedAutism Spectrum DisordersUnited States
-
University Hospital, MontpellierCaisse Nationale de Solidarité pour l'AutonomieActive, not recruitingAutism Spectrum DisordersFrance
-
Institut National de la Santé Et de la Recherche...Completed
-
Linmarie SikichEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedAutism Spectrum DisordersUnited States
-
National Human Genome Research Institute (NHGRI)CompletedAutism Spectrum DisordersUnited States
-
University of California, San DiegoCompletedAutism Spectrum DisordersUnited States
-
Stanford UniversityNational Institute of Mental Health (NIMH)Completed
Clinical Trials on Riluzole
-
Aquestive TherapeuticsCovance; inVentiv Health ClinicalTerminatedAmyotrophic Lateral SclerosisUnited States
-
Uniformed Services University of the Health SciencesU.S. Army Medical Research and Development CommandCompleted
-
Peking University Third HospitalThe Second Hospital of Hebei Medical UniversityRecruitingAmyotrophic Lateral SclerosisChina
-
University of UtahOhio State UniversityRecruitingAtrial Fibrillation ParoxysmalUnited States
-
Aquestive TherapeuticsCovance; Inventiv HealthWithdrawn
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
AOSpine North America Research NetworkCompletedCervical Spondylotic MyelopathyUnited States, Canada
-
S. Andrea HospitalAgenzia Italiana del FarmacoCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedObsessive-compulsive Disorder | OcdUnited States